177Lu-DOTATATE治疗中骨髓吸收剂量及与血液学反应的相关性受图像剂量学方法和骨转移影响
该研究纳入46例接受至少2周期177Lu-DOTATATE治疗的晚期神经内分泌肿瘤患者,比较平面法与4种基于SPECT的混合方法估算骨髓吸收剂量,并分析其与血小板下降的相关性。结果显示不同方法估算的骨髓吸收剂量中位数从0.19至0.46 Gy/7.4 GBq不等,所有方法均与血小板下降显著相关,且骨转移患者骨髓吸收剂量较无骨转移者高3%-69%。
要点
- 不同图像剂量学方法估算的骨髓吸收剂量存在差异,平面法最低(0.19 Gy/7.4 GBq),T-SPECT最高(0.46 Gy/7.4 GBq)。
- 所有方法估算的骨髓吸收剂量均与血小板下降显著相关,第2周期后相关性增强(rs -0.49至-0.63)。
- 无骨转移患者中平面法相关性更强(rs=-0.67),有骨转移患者中混合方法相关性更强(rs=-0.61至-0.74)。
核心结论
- 基于图像技术估算的骨髓吸收剂量及其与血小板的相关性受测量椎体选择和骨转移存在与否的影响。
研究设计与样本
- 研究纳入46例在Sahlgrenska大学医院接受至少2周期177Lu-DOTATATE治疗的晚期神经内分泌肿瘤患者。
- 在注射后2、24、48、168小时采集平面图像,自动勾画高摄取和低摄取区室。
- 骨髓吸收剂量由高、低摄取区室的交叉剂量和自剂量计算,低摄取区室的时间-活度浓度曲线在平面法中用固定常数1.8校正,在4种混合方法中用注射后24小时SPECT图像中椎体活度浓度校正。
- 4种混合方法分别为L4-SPECT(L4椎体活度浓度)、V-SPECT(所有可见椎体中位活度浓度)、L-SPECT(腰椎中位活度浓度)、T-SPECT(胸椎中位活度浓度)。
主要发现
- 平面法、L4-SPECT、V-SPECT、L-SPECT和T-SPECT估算的骨髓吸收剂量中位数分别为0.19、0.36、0.40、0.39和0.46 Gy/7.4 GBq,范围分别为0.12-0.33、0.15-1.44、0.19-1.71、0.21-1.60和0.18-2.12 Gy/7.4 GBq。
- 所有方法估算的骨髓吸收剂量均与血小板计数下降显著相关,第2周期后相关性增强,Spearman相关系数(rs)分别为平面法-0.49、L4-SPECT -0.61、V-SPECT -0.63、L-SPECT -0.63、T-SPECT -0.57。
- 无骨转移患者中平面法相关性增强(rs=-0.67),而混合方法在无骨转移患者中相关性较差、在有骨转移患者中相关性较强(rs=-0.61至-0.74)。
- 有骨转移患者的平均骨髓吸收剂量较无骨转移患者高3%-69%。
临床怎么用
- 临床在解读177Lu-DOTATATE治疗骨髓吸收剂量与血液学毒性关系时,需考虑所采用的图像剂量学方法及患者是否存在骨转移。
- 对于无骨转移患者,平面法估算的骨髓吸收剂量与血小板下降相关性较好;对于有骨转移患者,混合方法的相关性更强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to compare different image-based methods for bone marrow dosimetry and study the dose-response relationship during treatment with 177Lu-DOTATATE in patients with and without skeletal metastases. Methods: This study included 46 patients with advanced neuroendocrine tumors treated with at least 2 fractions of 177Lu-DOTATATE at Sahlgrenska University Hospital. High- and low-uptake compartments were automatically outlined in planar images collected at 2, 24, 48, and 168 h after injection. The bone marrow absorbed doses were calculated from the cross doses of the high- and low-uptake compartments and the self-dose, using the time-activity concentration curve for the low-uptake compartment. This time-activity concentration curve was adjusted using a fixed constant of 1.8 for the planar dosimetry method and using the activity concentrations in vertebral bodies in SPECT images at 24 h after injection of 177Lu-DOTATATE in 4 hybrid methods: L4-SPECT used the activity concentration in the L4 vertebra, whereas V-SPECT, L-SPECT, and T-SPECT used the median activity concentration in all visible vertebrae, lumbar vertebrae, and thoracic vertebrae, respectively. Results: Using the planar method, L4-SPECT, V-SPECT, L-SPECT, and T-SPECT, the estimated median bone marrow absorbed doses were 0.19, 0.36, 0.40, 0.39, and 0.46 Gy/7.4 GBq, respectively, with respective ranges of 0.12-0.33, 0.15-1.44, 0.19-1.71, 0.21-1.60, and 0.18-2.12 Gy/7.4 GBq. For all methods, the bone marrow absorbed dose significantly correlated with decreased platelet counts. This correlation increased after treatment fraction 2: the Spearman correlation (rs) were -0.49 for the planar method, -0.61 for L4-SPECT, -0.63 for V-SPECT, -0.63 for L-SPECT, and -0.57 for T-SPECT. A separate analysis revealed an increased correlation for patients without skeletal metastases using the planar method (rs = -0.67). In contrast, hybrid methods had poor correlations for patients without metastases and stronger correlations for patients with skeletal metastases (rs = -0.61 to -0.74). The mean bone marrow absorbed doses were 3%-69% higher for patients with skeletal metastases than for patients without. Conclusion: The estimated bone marrow absorbed doses by image-based techniques and the correlation with platelets are influenced by the choice of measured vertebrae and the presence of skeletal metastases.
引用
- Hagmarker L, Svensson J, Rydén T, et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med. 2019. PMID: 30902877. doi:10.2967/jnumed.118.225235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。